Cytokinetics, Incorporated announced that an oral presentation of results from its phase IIa “Evidence of Effect” (EoE) clinical trial of CK-2017357 in patients with Amyotrophic Lateral Sclerosis (ALS) is scheduled to be presented as part of the Clinical Trials Session at the 21st International Symposium on ALS/MND, to be held December 11-13, 2010 in Orlando, Florida.

CK-2017357, a fast skeletal muscle troponin activator, is the lead drug candidate from the company’s skeletal muscle contractility program and the subject of a Phase II a clinical trials program in patients with ALS and in patients with symptoms of claudication associated with peripheral artery disease.

The International Symposium on ALS/MND is a unique annual event that brings together leading international researchers and health and social care professionals to present and debate key innovations in their respective fields. The International Symposium is the premier forum for both biomedical research and clinical investigation and practice for those interested in improving care, understanding disease pathogenesis and developing novel treatments for ALS/MND.

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility programme, omecamtiv mecarbil (formerly CK-1827452), is in clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights.